Unispeed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 12-08-2024
- Paid Up Capital ₹ 3.35 Cr
as on 12-08-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 14.55 Cr
as on 12-08-2024
- Satisfied Charges ₹ 16.85 Cr
as on 12-08-2024
- Revenue 2.29%
(FY 2023)
- Profit 18.65%
(FY 2023)
- Ebitda 0.63%
(FY 2023)
- Net Worth 43.35%
(FY 2023)
- Total Assets 9.46%
(FY 2023)
About Unispeed Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.35 Cr.
The company currently has active open charges totaling ₹14.55 Cr. The company has closed loans amounting to ₹16.85 Cr, as per Ministry of Corporate Affairs (MCA) records.
Satish Kumar, Mayank Singhal, Daman Singhal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230HP2005PTC007610
- Company No.
007610
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Baddi, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Unispeed Pharmaceuticals Private Limited offer?
Unispeed Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Cleaning Liquids & Wipes, Kitchen Cleaners, Digestive System Drugs & Medicines, Gastrointestinal Drugs, Diclofenac, Common Disease Medicines, Allopathic Cough Syrup, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Unispeed Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Daman Singhal  | Director | 08-Dec-2017 | Current |
| Satish Kumar | Director | 20-Nov-2017 | Current |
| Mayank Singhal | Director | 08-Dec-2017 | Current |
| Manoj Sharma | Additional Director | 19-Jan-2024 | Current |
Financial Performance and Corporate Structure Insights of Unispeed Pharmaceuticals.
Unispeed Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.29% increase. The company also saw a substantial improvement in profitability, with a 18.65% increase in profit. The company's net worth Soared by an impressive increase of 43.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unispeed Pharmaceuticals?
In 2023, Unispeed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Smd Chemi-Pharma Private LimitedActive 26 years 1 monthSatish Kumar and Daman Singhal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Dec 2021 | ₹5.00 M | Open |
Hdfc Bank Limited Creation Date: 07 Jul 2021 | ₹2.00 M | Open |
Hdfc Bank Limited Creation Date: 15 Dec 2020 | ₹13.85 Cr | Open |
How Many Employees Work at Unispeed Pharmaceuticals?
Unispeed Pharmaceuticals has a workforce of 52 employees as of Aug 12, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unispeed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unispeed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
